Search Results
Mar 20, 2026, 09:23 ET Henlius Reports 2025 Results: Sustained Growth in Both Revenue and Profit, Advancing Innovation Validation and Global Operations
of HLX14 (denosumab) have been commercially launched in the United States as well as in Germany, Spain and the UK, generating sales revenue of RMB 9.8 million during the reporting period. Meanwhile, Henlius continues to advance its innovation pipeline, with key assets including dulpatatug (HLX22, novel
More news about: Henlius
Mar 20, 2026, 09:03 ET 復宏漢霖2025年業績：收入利潤持續雙增長，體系出海加速落地，創新管線進入密集驗證期
Club平台在內的多維技術平台。業績期內，HLX37（PD-L1 x VEGF雙抗）、HLX97（KAT6A/B小分子抑制劑）、HLX3901（DLL3 x DLL3 x CD3 x CD28四抗TCE）、HLX316（B7-H3唾液酸酶融合蛋白）等分子獲得新藥臨床試驗批准。同時，公司持續推進多款潛力候選分子研發，包括HLX3902（STEAP1 x CD3 x CD28三抗TCE）、HLX48（EGFR x cMET雙抗ADC）、HLX49（HER2雙表位ADC）、HLX109（IL-1R3單抗）等，持續豐富具備全球競爭力的創新管線。作為全球化2.0的重要基礎，復宏漢霖持續
More news about: 復宏漢霖
Mar 20, 2026, 09:03 ET Henlius Reports 2025 Results: Sustained Growth in Both Revenue and Profit, Advancing Innovation Validation and Global Operations
discovery and development. During the reporting period, multiple candidates—including HLX37 (PD-L1 × VEGF bispecific antibody), HLX97 (KAT6A/B small-molecule inhibitor), HLX3901 (DLL3 × DLL3 × CD3 × CD28 tetra-specific TCE), and HLX316 (B7-H3 sialidase fusion protein)—received Investigational New Drug (IND) approvals.
More news about: Henlius
Feb 05, 2026, 06:44 ET Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
worldwide with an accelerated globalisation process. In parallel, multiple high-potential innovative assets—including the PD-L1 ADC HLX43 and the novel epitope anti-HER2 mAb HLX22—are advancing through global pivotal clinical development. Supported by a biologics manufacturing network with a total capacity
More news about: Henlius
Jan 19, 2026, 02:00 ET Henlius präsentiert auf der JPM 2026 die Strategie „Globalisation 2.0" sowie einen mittel- bis langfristigen Innovationsfahrplan
Innovationskandidaten im Jahr 2026 vor, darunter Serplulimab (Handelsname: Hetronifly® in Europa), ein Anti-PD-1-MAb; HLX22, ein neuartiger Epitop-Anti-HER2-MAb; HLX43, ein PD-L1-ADC; und HLX07, ein Anti-EGFR-MAb.Derzeit umfasst das präklinische Portfolio des Unternehmens mehrere molekulare Modalitäten,
More news about: Henlius
Jan 19, 2026, 02:00 ET Henlius presenta su estrategia "Globalización 2.0" y su plan de innovación a medio y largo plazo en JPM 2026
activos de innovación clave en 2026, incluidos serplulimab (nombre comercial: Hetronifly® en Europa), un mAb anti-PD-1; HLX22, un nuevo mAb anti-HER2 de epítopo; HLX43, un ADC PD-L1; y HLX07, un mAb anti-EGFR.Actualmente, la cartera de activos preclínicos de la Compañía abarca múltiples modalidades
More news about: Henlius
Jan 19, 2026, 02:00 ET Henlius présente sa stratégie « Globalisation 2.0 » et son plan d'innovation à moyen et long terme lors de la conférence JPM 2026
actifs innovants en 2026, notamment le serplulimab (nom commercial : Hetronifly® en Europe), un AcM anti-PD-1 ; le HLX22, un AcM anti-HER2 à nouvel épitope ; le HLX43, un ADC PD-L1 ; et le HLX07, un AcM anti-EGFR.Actuellement, le portefeuille d'actifs précliniques de la société couvre de multiples
More news about: Henlius
Jan 16, 2026, 08:00 ET Henlius Showcases "Globalisation 2.0" Strategy and Mid-to-Long-Term Innovation Blueprint at JPM 2026
in the Japanese bridging study for ES-SCLC.HLX22 – Novel Epitope Anti-HER2 mAb with a Differentiated ModalityPhase 2 data readout in HER2-low breast cancer in China is expected in the first half of 2026.HLX43 – PD-L1 ADC ("Pipeline-in-a-Pill") with High-Efficacy, a
More news about: Henlius
Jan 16, 2026, 07:30 ET Henlius Showcases "Globalisation 2.0" Strategy and Mid-to-Long-Term Innovation Blueprint at JPM 2026
for its key innovation assets in 2026, including serplulimab (trade name: Hetronifly® in Europe), an anti-PD-1 mAb; HLX22, a novel epitope anti-HER2 mAb; HLX43, a PD-L1 ADC; and HLX07, an anti-EGFR mAb.At present, the Company's preclinical asset portfolio spans multiple molecular modalities, including
More news about: Henlius
Dec 21, 2025, 20:00 ET 復星國際榮獲TVB頒發最高級別的「ESG年度卓越大獎」
癌症患者。其中，自主研發的創新型抗PD-1單抗H藥漢斯狀，是全球首個獲批用於一線治療小細胞肺癌的抗PD-1單抗。截至目前，H藥已在中國、歐盟、英國、新加坡、印度等近40個國家和地區獲批上市。今年以來，復星在創新藥領域實現多點破局。HLX43是一款靶向PD-L1的抗體偶聯藥物（ADC），正在中、美、澳等國家開展非小細胞肺癌、胸腺癌等實體瘤的臨床研究。目前，全球範圍內尚無PD-L1 ADC獲批上市，HLX43有潛力成為高效、安全的「廣譜抗癌藥」。12月7日，國家醫保局、人力資源社會保障部發佈2025年國家醫保目錄，復星醫藥旗下多款已上市的產品獲納入，而備受關注的首版商保
More news about: 復星
Dec 21, 2025, 20:00 ET Fosun International Honored with TVB's Highest Accolade, "Outstanding ESG Award"
drugs. HLX43, a PD-L1-targeting antibody-drug conjugate (ADC), is undergoing clinical studies for solid tumors such as non-small cell lung cancer and thymic carcinoma in countries including China, the United States, and Australia. Currently, no PD-L1 ADC has been approved globally, positioning HLX43 as
More news about: Fosun
Dec 01, 2025, 17:31 ET Colorectal Cancer Market Set to Expand Throughout Forecast Period (2025-2034) Driven by Increasing Screening Rates and Novel Drug Approvals | DelveInsight
and immuno-oncology agents are expanding treatment options and prolonging patient survival. Additionally, the launch of emerging therapies such as Serplulimab (HLX10) + Bevacizumab + Chemotherapy (Shanghai Henlius Biotech), Botensilimab ± Balstilimab (Agenus), TTX-080 (Tizona Therapeutics), SGM-101 (Surgimab), HRO761
More news about: DelveInsight Business Research, LLP
Nov 20, 2025, 20:00 ET 復星國際榮獲《彭博商業周刊中文版》頒發「ESG 領先企業大獎」
5萬患者。其中，自主研發的創新型抗PD-1單抗H藥漢斯狀，是全球首個獲批用於一線治療小細胞肺癌的抗PD-1單抗。截至目前，H藥已在中國、歐盟、英國、新加坡、印度等近40個國家和地區獲批上市。今年以來，復星在創新藥領域實現多點破局。HLX43是一款靶向PD-L1的抗體偶聯藥物（ADC），正在中、美、澳等國家開展非小細胞肺癌、胸腺癌等實體瘤的臨床研究。目前，全球範圍內尚無PD-L1 ADC獲批上市，HLX43有潛力成為高效、安全的「廣譜抗癌藥」。此外，在小分子創新藥方面，復星自研的靶向藥物復邁寧獲批兩項罕見病適應症，填補了相關罕見病腫瘤領域的治療空白。立業為善，積
More news about: 復星
Nov 20, 2025, 20:00 ET Fosun International Honored as "ESG Leading Enterprise" by Bloomberg Businessweek/Chinese Edition
drugs. HLX43, a PD-L1-targeting antibody-drug conjugate (ADC) is undergoing clinical studies for solid tumors such as non-small cell lung cancer and thymic carcinoma in countries including China, the United States, and Australia. Currently, no PD-L1 ADC has been approved globally, positioning HLX43 as
More news about: Fosun
Nov 11, 2025, 02:34 ET Guo Guangchang: Fosun Strengthens Globalization Capabilities, Accelerates Innovation through Open Cooperation
treatment. In addition to HANSIZHUANG, Henlius' R&D pipeline features several highly promising innovative products. Among which, HLX43, a PD-L1-targeting antibody-drug conjugate (ADC) is undergoing clinical studies for solid tumors such as non-small cell lung cancer and thymic carcinoma
More news about: Fosun
Nov 06, 2025, 20:00 ET 復星國際榮獲《財資》雜誌頒發的「2025年財資企業永續領導獎金獎」及「最佳可持續發展團隊獎」
全球首個獲批用於一線治療小細胞肺癌的抗PD-1單抗。截至目前，H藥已在中國、歐盟、英國、新加坡、印度等近40個國家和地區獲批上市，惠及全球逾11萬名患者。 今年以來，復星在創新藥領域實現多點破局。HLX43是一款靶向PD-L1的抗體偶聯藥物（ADC），正在中、美、日、澳等國家開展非小細胞肺癌、胸腺癌等實體瘤的臨床研究。目前，全球範圍內尚無PD-L1 ADC獲批上市，HLX43有潛力成為高效、安全的「廣譜抗癌藥」。此外，在小分子創新藥方面，復星自研的靶向藥物復邁寧獲批兩項罕見病適應症，填補了相關罕見病腫瘤領域的治療空白。
More news about: 復星
Nov 06, 2025, 20:00 ET Fosun International Honored with Gold Award and Best Sustainability Team at The Asset Corporate Sustainability Leadership Awards 2025
patients worldwide. Since the beginning of this year, Fosun has achieved multiple breakthroughs in the field of innovative drugs. HLX43, a PD-L1-targeting antibody-drug conjugate (ADC) is undergoing clinical studies for solid tumors such as non-small cell lung cancer and thymic carcinoma
More news about: Fosun
Oct 28, 2025, 08:11 ET Fosun Pharma Announces 2025Q3 Financial Results
radiopharmaceuticals and cell therapy, as well as global multicenter clinical trials of high-value pipelines, including HLX22 (recombinant humanized anti-HER2 monoclonal antibody injection) and HLX43 (PD-L1-targeted antibody-drug conjugate). Fosun Pharma's self-developed innovative anti-PD-1
More news about: Fosun Pharma
Oct 16, 2025, 23:13 ET Wang Qunbin: Innovation-Driven, Fosun's Path to Globalization
in the future. Since the beginning of this year, Fosun has achieved multiple breakthroughs in the field of innovative drugs. HLX43, a PD-L1-targeting antibody-drug conjugate (ADC) is undergoing clinical studies for solid tumors such as non-small cell lung cancer and thymic carcinoma
More news about: Fosun
Oct 16, 2025, 22:53 ET 汪群斌：以創新驅動，復星全球化攀登之路
值得一提的是，10月9日，H藥胃癌圍手術期III期臨床研究達到了主要終點，支持提前申報上市。這意味着，未來，胃癌患者在術前和術後有望不再需要進行輔助化療。 今年以來，復星在創新藥領域實現多點破局。HLX43是一款靶向PD-L1的抗體偶聯藥物（ADC），正在中、美、日、澳等國家開展非小細胞肺癌、胸腺癌等實體瘤的臨床研究。目前，全球範圍內尚無PD-L1 ADC獲批上市，HLX43有潛力成為高效、安全的「廣譜抗癌藥」。此外，在小分子創新藥方面，復星自研的靶向藥物復邁寧獲批兩項罕見病適應症，填補了相關罕見病腫瘤領域的治療空白。
More news about: 復星
Oct 09, 2025, 08:22 ET Phase 3 Clinical Trial of HANSIZHUANG Plus Chemotherapy Meets Primary Endpoint in Neoadjuvant/Adjuvant Gastric Cancer, Greenlighting Early NDA Submission
outcomes achieved with HANSIZHUANG in the neoadjuvant/adjuvant setting, the company's internally developed, differentiated novel epitope HER2 mAb, HLX22, is challenging the current first-line standard of care for HER2-positive advanced gastric cancer through an international multi-centre, head-to-head
More news about: Henlius
Oct 09, 2025, 07:38 ET 開創無化療時代：全球首個H藥胃癌圍手術期III期臨床研究達到主要終點，支持提前申報上市
[3] Issafras H, et al. Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy. PLoS One. 2021;16(12):e0257972.
More news about: 復宏漢霖
Sep 16, 2025, 17:31 ET KAT6 Inhibitors Market Poised for Significant Growth During the Forecast Period (2025-2040) | DelveInsight
inhibitors market in the coming years. Some of the key KAT6 inhibitors in clinical trials include PF-07248144, MEN2312, OP-3136, BG-75202, IDE251, HLX97-069, HW321005, QLS1304, IST-477, and others.Discover which indication is expected to grab the major KAT6 inhibitors market share @
More news about: DelveInsight Business Research, LLP